Skip to main content
. 2019 Nov 8;3(1):58–66. doi: 10.31662/jmaj.2019-0005

Figure 1.

Figure 1.

Progression-free survival in NSCLC patients, with or without immune-related adverse events, based on (1) all patients (n = 44), (2) patients treated with pembrolizumab as the primary therapy (n = 22), and (3) patients treated with pembrolizumab as secondary or more therapy (n = 22).

Ticks indicate patients whose data were censored on April 30, 2018. irAE, immune related adverse event; NR, not reached.